| 四川科倫博泰生物醫藥股份有限公司 - H股, 06990.HK - 綜合損益表 |
2022-12 |
2021-12 |
| 營業額 |
803,933 |
32,322 |
| 經營溢利 |
-418,550 |
-777,204 |
| 非經營/ 特殊項目 |
0 |
0 |
| 聯營公司 |
0 |
0 |
| 除稅前經營溢利 |
-567,364 |
-889,795 |
| 稅項 |
48,735 |
0 |
| 少數股東權益 |
0 |
0 |
| 股東應占溢利 |
-548,099 |
-822,550 |
| 貨幣 |
人民幣 |
人民幣 |
| 單位 |
| 主要項目 |
| 折舊 |
67,364 |
22,914 |
| 利息 |
157,742 |
119,242 |
| 利息撥作發展資本 |
8,928 |
6,651 |
| 處置/重估固定資產 |
0 |
0 |
| 稅率(%) |
-8.59 |
|
| 營業額增長(%) |
0.0 |
0.0 |
| 股東應占溢利增長(%) |
0.0 |
0.0 |
| 核數師意見 |
0 |
0 |
說明：1代表無保留意見；2代表保留意見；3代表修改意見
|
We've noticed you're using an ad blocker
We spend millions of dollars each year so you can access, for FREE, the highest quality real-time quotes and charts. This is made possible only thanks to the advertising on our site.
To continue using 88iv.com, please allow this domain on your ad blocker.
We are thanksful for your decisive action.
This notice will be shown again every hour.
Close This Window